Author

K. Purushotorman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 4 Approach:experimental assay· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:mechanistic / dynamical model· 2 Organism:virus· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

P. A. MacAry· 3 shared X. Qian· 3 shared F. Samsudin· 2 shared G. Yue· 2 shared J. Lescar· 2 shared M. K. McQueen· 2 shared N. K. Tulsian· 2 shared A. D. T. Barrett· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

P. A. MacAry

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Single shot dendritic cell targeting SARS-CoV-2 vaccine candidate induces broad and durable systemic and mucosal immune responses

N. Y. Z. Cheang, P. S. Tan, K. Purushotorman, W. C. Yap, B. Y. L. Chua, K. S. Tan, K. M. Tullett, A. Y.-Y. Yeoh, C. Q. H. Tan, X. Qian, D. J. W. Tay, I. Caminschi, Y. J. Tan, P. A. MacAry, C. W. Tan, , S. Alonso

This study evaluates a SARS-CoV-2 vaccine candidate that targets dendritic cells, showing durable systemic and mucosal immune responses against multiple variants.

bioRxiv · Feb 21, 2023 · PreprintImmunology

Mapping the allosteric effects that define functional activity of SARS-CoV-2 specific antibodies

N. K. Tulsian, P. V. Raghuvamsi, X. Qian, G. Yue, B. D/O Shunmuganathan, F. Samsudin, Y. H. Wong, L. Jianqing, K. Purushotorman, M. K. McQueen, B. Wang, J. Lescar, C.-I. Wang, G. Anand, P. J. Bond, P. A. MacAry

This study identifies site-specific allosteric effects in SARS-CoV-2 Spike protein induced by different neutralizing antibodies, revealing dynamic features that distinguish weak from strong neutralizers.

bioRxiv · Dec 27, 2021 · PreprintBiochemistry

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

C. E. Z. Chan, S. G. K. Seah, D. H. Chye, S. Massey, M. Torres, A. P. C. Lim, S. K. K. Wong, J. J. Y. Neo, P. S. Wong, J. H. Lim, G. S. L. Loh, D. L. Wang, J. D. Boyd-Kirkup, S. Guan, D. Thakkar, , B. J. Hanson

The paper identifies SC31, a potent SARS-CoV-2 neutralizing antibody, and shows that its Fc-mediated effector functions are critical for its therapeutic efficacy in vivo.

bioRxiv · Oct 26, 2020Microbiology

SARS-CoV-2 S protein ACE2 interaction reveals novel allosteric targets

G. S. Anand, R. Palur, N. K. Tulsian, F. Samsudin, X. Qian, K. Purushotorman, G. Yue, M. K. McQueen, J. Lescar, P. Bond, P. A. McAry

The paper investigates how ACE2 binding to SARS-CoV-2 Spike protein allosterically affects proteolysis at distal cleavage sites and highlights potential therapeutic targets.

bioRxiv · Oct 13, 2020Biochemistry